U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H34Cl2N4O7
Molecular Weight 669.552
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BECATECARIN

SMILES

CCN(CC)CCN1C(=O)C2=C(C1=O)C3=C(N([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)C5=C3C=CC=C5Cl)C6=C2C7=C(N6)C(Cl)=CC=C7

InChI

InChIKey=JSKFWUPVIZYJMR-UDOAKELVSA-N
InChI=1S/C33H34Cl2N4O7/c1-4-37(5-2)12-13-38-31(43)22-20-15-8-6-10-17(34)24(15)36-25(20)27-21(23(22)32(38)44)16-9-7-11-18(35)26(16)39(27)33-29(42)28(41)30(45-3)19(14-40)46-33/h6-11,19,28-30,33,36,40-42H,4-5,12-14H2,1-3H3/t19-,28-,29-,30-,33-/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H34Cl2N4O7
Molecular Weight 669.552
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/11387367 http://www.ncbi.nlm.nih.gov/pubmed/12678746

Rebeccamycin analog (RA, Becatecarin/ BMS 181176, rebeccamycin derivative, NSC 655649) is an antitumor antibiotic with inhibitory activity against both topoisomerase I and II, and DNA-intercalating properties. The mechanism of action of becatecarin is not exactly known, but it is thought that by inhibiting (blocking) the function of topoisomerase enzymes, it will destroy cancer cells and slow down the growth of the tumour. On 25 July 2006, orphan designation (EU/3/06/388) was granted by the European Commission to Helsinn Birex Pharmaceuticals Ltd, Ireland, for becatecarin for the treatment of cancers of the biliary tree.

Originator

Curator's Comment: # Bristol-Myers Squibb

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.3 μg/mL
744 mg/m² single, intravenous
dose: 744 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BECATECARIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14.5 μg/mL
572 mg/m² single, intravenous
dose: 572 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BECATECARIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
83.7 μg × h/mL
744 mg/m² single, intravenous
dose: 744 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BECATECARIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5262 μg × min/mL
572 mg/m² single, intravenous
dose: 572 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BECATECARIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
73.2 h
744 mg/m² single, intravenous
dose: 744 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BECATECARIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28.8 h
572 mg/m² single, intravenous
dose: 572 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BECATECARIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Becatecarin (Helsinn Healthcare).
2005 Oct
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
2009 Aug
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.
2011 Feb
Patents

Patents

Sample Use Guides

Recommended phase II doses are 500 mg/m(2) and 572 mg/m(2) IV once every 3 weeks for heavily pretreated (HP) patients and minimally pretreated (MP) respectively
Route of Administration: Intravenous
In Vitro Use Guide
Tumor cells from 14 established cell lines and 20 patient specimens were exposed in vitro for 1 hour to NSC# 655649 (rebeccamycin tartrate salt ) at concentrations ranging from 0.015 to 15.0 uM. The cytotoxicity (IC50) of this agent against established cell lines was determined using both the MTT (cytotoxic) and clonogenic/soft agar cloning (cytostatic) assays. Tumor specimens from children undergoing biopsy or surgical resection were also evaluated in vitro against NSC# 655649 using the clonogenic assay. For studies using patient specimens, antitumor activity was measured by comparing the number of tumor colonies from NSC# 655649-treated cells with those from solvent-treated controls.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:44:33 UTC 2023
Edited
by admin
on Fri Dec 15 15:44:33 UTC 2023
Record UNII
A60X6MBU6G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BECATECARIN
INN   MART.   USAN   WHO-DD  
INN   USAN  
Official Name English
BMS-181176
Code English
NSC-655649
Code English
6-(2-(DIETHYLAMINO)ETHYL)-REBECCAMYCIN
Common Name English
Becatecarin [WHO-DD]
Common Name English
XL119
Code English
5H-INDOLO(2,3-A)PYRROLO(3,4-C)CARBAZOLE-5,7(6H)-DIONE, 1,11-DICHLORO-6-(2-(DIETHYLAMINO)ETHYL)-12,13-DIHYDRO-12-(4-O-METHYL-.BETA.-D-GLUCOPYRANOSYL)-
Common Name English
DEAE-REBECCAMYCIN
Common Name English
BMY-27557
Code English
XL-119
Code English
BECATECARIN [MART.]
Common Name English
BECATECARIN [USAN]
Common Name English
becatecarin [INN]
Common Name English
1,11-DICHLORO-6-(2-(DIETHYLAMINO)ETHYL)-12,13-DIHYDRO-12-(4-O-METHYL-.BETA.-D-GLUCOPYRANOSYL)-5H-INDOLO(2,3-A)PYRROLO(3,4-C)CARBAZOLE-5,7(6H)-DIONE
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/06/388
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
FDA ORPHAN DRUG 179903
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
NCI_THESAURUS C582
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
NCI_THESAURUS C1904
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
Code System Code Type Description
CAS
119673-08-4
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
NCI_THESAURUS
C1620
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
NSC
655649
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
PUBCHEM
101524
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
USAN
QQ-56
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
EPA CompTox
DTXSID60869635
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
ChEMBL
CHEMBL2107313
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
INN
8564
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
DRUG BANK
DB06362
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
SMS_ID
100000089433
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
FDA UNII
A60X6MBU6G
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
MESH
C093269
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
EVMPD
SUB25405
Created by admin on Fri Dec 15 15:44:33 UTC 2023 , Edited by admin on Fri Dec 15 15:44:33 UTC 2023
PRIMARY
Related Record Type Details
TARGET->LIGAND
Related Record Type Details
ACTIVE MOIETY